Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 ,inter alia, to consider and approve Unaudited Standalone ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aspira Pathlab & Diagnostics has informed BSE that its Board of Directors will meet on Wednesday, November 12, 2025. The agenda includes consideration and approval of the Unaudited Standalone and Consolidated Financial Results along with the Limited Review Report for the second quarter and half year ended September 30, 2025. Other routine business items may also be discussed. The notice has been issued under Regulation 29(1) of the SEBI LODR Regulations, 2015. No financial figures or outcomes are disclosed in this intimation — only the meeting schedule.
This is a standard pre-results intimation with no immediate impact on shareholders. Investors should watch for the actual Q2/H1 FY26 results, which will be announced after the November 12 board meeting.